ANTHEM

The recent quarterly results for Q3 FY25-26 presented a challenging picture. Profit before tax (PBT) excluding other income fell sharply by 24.2% to ₹122.31 crores compared to the previous four-quarter average. Similarly, profit after tax (PAT) declined by 14.1% to ₹110.87 crores, while net sales dropped to ₹423.15 crores, marking the lowest quarterly sales figure in recent periods. However, these short-term setbacks contrast with the company’s healthy long-term growth trajectory. Anthem Biosciences has achieved a compound annual growth rate (CAGR) of 29.80% in net sales and an even more impressive 44.32% growth in operating profit over the longer term. Additionally, profits have risen by 35% over the past year, signalling underlying strength in the business model and market positioning.